瑞莎珠与司库奇尤治疗中重度斑块型银屑病患者的对比（IMMerge）：III期试验
在Medfyle内
专家评论 Kirk Barber, MD, FRCPC, FCDA, FAAD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the AAD Virtual Meeting Experience and presented by:
Richard B. Warren, BSc (Hons), MBChB (Hons), PhD
The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, UK
Manchester NIHR Biomedical Research Centre, Manchester, UK
The content is produced by Infomedica, the official reporting partner of ADA 2020 Virtual Meeting. The summary text was drafted by Synthesis Editorial Ltd, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Hassan Galadari, MD, FAAD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Kirk Barber, MD, FRCPC, FCDA, FAAD
University of Calgary, Calgary, Alberta, Canada
About the Expert
Kirk Barber, MD, FRCPC, FCDA, FAAD
University of Calgary, Calgary, Alberta, Canada
Dr. Barber obtained his MD from the University of Alberta and his Canadian Fellowship in Dermatology (FRCPC) after training in Internal Medicine at the University of Alberta and Dermatology at the University of Ottawa and Harvard Medical School. As the Chief Resident in Dermatology at Harvard Medical School he qualified as a Diplomate of the American Academy of Dermatology (FAAD). Dr. Barber is in private clinical practice and is a Clinical Professor in both the Departments of Medicine (Dermatology) and Community Health Sciences in the Faculty of Medicine at the University of Calgary. Dr. Barber has been the Principal Investigator in over 150 national and international clinical research trials. Dr. Barber served as the Chair of the Health Research Ethics Board of Alberta Clinical Trials Committee (a committee that reviews all human medical research conducted outside Alberta’s major universities) for 15 years resigning in 2015. Dr. Barber is the Editor-in-Chief of the indexed, peer reviewed journal of the Canadian Dermatology Association - the “Journal of Cutaneous Medicine and Surgery” and the on-line journal the “Journal of Cutaneous Medicine and Surgery Case Reports”. Dr. Barber is an active podcaster hosting JCMS Author Interviews twice monthly. Dr. Barber was President of the Canadian Dermatology Association (CDA) in 2003 and he has received the CDA’s Presidents Cup twice (1997, 2011) recognizing his outstanding and continuing contributions to the CDA.
References
1. De Carvalho AVE, Duquia RP, Horta BL, Bonamigo RR. Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs in R&D 2017;17:29–51.
2. Boehncke W-H, Brembilla NA. Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. Clin Rev Allergy Immunol 2018;55:295–311.
3. Puig L, Thom H, Mollon P, Ramakrishna GS. Clear or Almost Clear Skin Improves the Quality of Life in Patients With Moderate-To-Severe Psoriasis: A Systematic Review and Meta-Analysis. JEADV 2017;31:213–20.
